Haisco Pharmaceutical Group (002653.SZ) plans to raise no more than 1.365 billion yuan for new drug research and development projects and supplementing working capital.

Haisco Pharmaceutical Group (002653.SZ) disclosed a plan to issue A shares to specific targets in 2025. The company intends to issue shares to no more than 35 specific investors, with a quantity not exceeding 70 million shares. The issue price shall not be lower than 80% of the average trading price of the company's stock in the 20 trading days prior to the pricing reference date. In addition, the total amount of funds raised through the issuance of shares to specific targets this time shall not exceed 1.365 billion yuan, which will be invested in new drug research and development projects and supplementary working capital after deducting issuance expenses.